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42 Markov and 19 MC. Median time since publication was 6 years. Most models 
concerned Type 2 DM (57%) and prevention or disease-management programs 
(54%). In average, models had 11 states and 2.8 complications. MC were signiﬁ cantly 
more used than Markov when both type 1 and 2 DM and a prevention or disease 
management program were concerned. Models had, signiﬁ cantly, a higher number of 
states and complications. The choice of the model type was shown to be inﬂ uenced 
by the number of DM and of complications considered. The justiﬁ cation to perform 
a Monte-Carlo was more often documented than those to perform a Markov (74% 
vs. 38%). The model was considered accurate with the study question in respectively 
86% of Monte-Carlo and 64% of Markov. CONCLUSIONS: This study allowed to 
statistically identify factors inﬂ uencing the type of model used to simulate DM. It is 
an interesting tool for modelers in their decision process to build a model. Information 
such as data and time availability or ﬁ nancial context could not be collected.
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OBJECTIVES: In the last 15 years, models built to appraise health technologies have 
grown in complexity to accurately reﬂ ect the natural history of disease and calculate 
costs and beneﬁ ts accordingly. The advantage of using patient level simulation models 
(PSM) over cohort models (CM) is that CM may become unwieldy with thousands 
of branches. This usually happens if the patient characteristics inﬂ uence the risks of 
complications and these vary over time, or if there are many comorbidities to take 
into account and the risk of each complication is time dependent. In this case, a typical 
Markov cohort may be unsuitable. However a PSM can take a long time to run in 
order to produce results. Aim of this research is to present a case study where a PSM 
is simpliﬁ ed with a Markov structure and to compare the results of the two models. 
METHODS: We describe how a PSM for diabetes may be adapted to a CM, stating 
all the limitations. RESULTS: Provided that the PSM gives similar answers to the CM, 
the CM may be used as a surrogate for conducting complex sensitivity analysis (e.g., 
3-way analysis or tornado diagrams). The advantage is that this model would produce 
results “instantaneously.” CONCLUSIONS: The adaptation of a PSM model to a 
cohort model may be a desirable feature if the model is required by a non technical 
audience. This is the case for “due diligence” models that are increasingly required by 
investors to assess the value of assets that a pharmaceutical company considers to buy 
or sell. Further research is needed to have a powerful test to assess whether the dif-
ference in results between a simpliﬁ ed CM model and the PSM are statistically 
signiﬁ cant. 
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: While the comorbidity burden of gout in the US has been considered 
substantial and may have been rising over the past decade, no contemporary national 
data are available. We estimated the prevalence of major comorbidities in patients 
with gout compared with those without gout based on a recent, nationally representa-
tive sample of US men and women (National Health and Nutrition Examination 
Survey [NHANES] 2007–2008). METHODS: Using data from 5707 participants in 
NHANES 2007–2008 (2797 men and 2910 women) aged 20 years and older, we 
determined the prevalence of major comorbidities among individuals with gout, 
including hypertension, renal impairment, nephrolithiasis, diabetes, myocardial infarc-
tion, heart failure, stroke, and obesity. We also compared the prevalence with those 
without gout using age- and sex-adjusted logistic regressions. Case deﬁ nitions of 
comorbidities were based on an afﬁ rmative answer to a question asking if a physician 
or a health professional had diagnosed the corresponding condition. RESULTS: 
Among US adults with gout, 74% had hypertension, 53% obesity, 26% diabetes, 24% 
nephrolithiasis, 14% myocardial infarction, 11% heart failure, 10% stroke, and 9% 
renal impairment (Table). Prevalence of these comorbidities among individuals with 
gout was substantially higher than among individuals without gout. Age- and sex-
adjusted odds ratios (95% conﬁ dence interval [CI]) were 4.19 (2.75–6.39) for hyper-
tension, 2.35 (1–55–3.57) for obesity, 2.36 (1.49–3.73) for diabetes, 2.10 (1.39–3.18) 
for nephrolithiasis, 2.37 (1.54–3.65) for myocardial infarction, 2.68 (1.88–3.83) for 
heart failure, 2.02 (0.98 to 4.19) for stroke, and 3.50 (2.05–5.98) for renal impair-
ment. CONCLUSIONS: These ﬁ ndings from the latest nationally representative 
sample of US adults in NHANES 2007–2008 conﬁ rm that the prevalence of comor-
bidities among individuals with gout is substantial and considerably higher than 
among individuals without gout.
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OBJECTIVES: Previous cohort studies using US commercial insurance claims of 
rheumatoid arthritis (RA) patients have observed higher dose escalation rates for 
patients treated with tumor necrosis factor-α (TNF) blockers inﬂ iximab (INF) or 
adalimumab (ADA) than for etanercept (ETN). However, such databases cannot be 
used to determine whether dose escalation is associated with improved clinical out-
comes. We compared functional disability and dosing history between patients treated 
with TNF blockers using data from a large, prospective observational registry (Arthri-
tis, Rheumatism, and Aging Medical Information System; ARAMIS) of RA patients 
in the US. METHODS: ARAMIS enrolled adult physician-diagnosed RA patients. 
Patients who met following inclusion criteria were selected: treated with a TNF 
blocker for ≥9 months; had no biologics 6 months before index TNF treatment; and 
reported a Health Assessment Questionnaire Disability Index (HAQ-DI) at index and 
9–15 months after index. Self-reported dosing information was validated by telephone 
follow-up, medical, billing, or retail pharmacy prescription records. Dose escalation 
was deﬁ ned as dosing above ﬁ rst ADA/ETN or third INF dose. Multivariate models 
compared HAQ-DI change and dose escalation rates, controlling for variables that 
differed among INF, ADA and ETN patients at index. RESULTS: Approximately 351 
patients (93 INF, 40 ADA, 218 ETN) met study criteria. Subjects were mostly female 
(83%), Caucasian (88%), and had mean disease duration of 18.9 years. HAQ-DI 
change scores at 9–15 months did not differ by treatment (−0.10, −0.08, and −0.12 
points for INF, ADA, and ETN, respectively; P = 0.52). Dose increases were observed 
in 1.4% of ETN patients, as compared with 10.8% of INF (P < 0.001) and 12.5% 
of ADA patients (P = 0.004, both vs. ETN). HAQ-DI change was associated with 
pre-index HAQ-DI score and disease duration (both P < 0.05). CONCLUSIONS: This 
study showed dose escalation in fewer ETN than INF or ADA patients, but similar 
improvements in functional disability.
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BACKGROUND: Cervical arthroplasty has been used successfully worldwide for over 
a decade in patients with cervical degenerative disc disease (CDDD). Several RCTs have 
documented the clinical advantage of arthroplasty vs. fusion for this patient population. 
Synthesis of outcomes from published RCTs is needed to consolidate the evidence-base 
for arthroplasty in CDDD. OBJECTIVES: To examine current evidence of safety and 
efﬁ cacy in the use of arthroplasty to treat CDDD and conduct a pooled analysis of high 
level comparative outcomes for arthroplasty versus fusion. METHODS: A systematic 
search of the PubMed, EMBASE, MEDLINE, CRD York, and Cochrane Library data-
bases, plus hand searching of grey literature was undertaken in January 2010. RESULTS: 
A total of 554 non-duplicate citations were retrieved. Only three studies of arthroplasty 
versus fusion with 2 years follow-up met all inclusion criteria and were of reasonable 
quality (according to GRADE criteria) to pool. a meta-analysis was conducted using 
RevMan5 software (Cochrane 2008). Persons undergoing single-level arthroplasty had 
signiﬁ cantly improved neurological success (RR 1.14, 95% CI [1.07, 1.21] P < 0.0001), 
Neck Disability Index (NDI) success (RR 1.13, 95% CI [1.05, 1.22] P = 0.001) and 
overall success (RR 1.22 95% CI [1.12, 1.33], P < 0.00001) at 2 years post surgery 
compared to fusion. Secondary surgeries (any revision, removal, or re-operation of the 
implant or supplemental ﬁ xation) after 2 years were also signiﬁ cantly lower with 
arthroplasty (13/621) compared to fusion (39/592), [0.32 95% CI [0.17, 0.59) P = 
0.0003]. Total number of patients undergoing reoperations at adjacent levels was lower 
in arthroplasty-treated patients (9/621) vs. ACDF (17/592), however it was not statisti-
cally signiﬁ cant (P = 0.09). Given the small numbers of patients undergoing reoperations 
at adjacent levels, longer term results are needed to increase precision of this estimate. 
CONCLUSIONS: A formal pooled analysis of 2-year RCT data demonstrates clinically 
signiﬁ cant improvements in efﬁ cacy and safety outcomes in CDDD patients who have 
undergone arthroplasty versus standard fusion.
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OBJECTIVES: To determine in patients with RA the number needed to treat (NNT) 
to achieve minimum clinically important differences (MCIDs) in multiple patient 
